🔎 Trials Near Me

Home › Adenocarcinoma of Lung › NCT03199651

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

Recruiting

Beating Lung Cancer in Ohio (BLCIO) Protocol

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* AIM 1-3
* Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group \[ECOG\] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;

  * Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)
* English speaking; and
* Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys
* AIM 3 ONLY
* Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (\< 3 months); and
* Household members must be current smokers, defined as smoking at least one cigarette most days per week
* Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection

Exclusion Criteria:

* Being treated with definitive chemoradiotherapy or surgery
* Receiving treatment for advanced lung cancer for over one month before enrollment; OR

About the study

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.

What is being tested

Sponsor: Ohio State University Comprehensive Cancer Center · Participants: 3,584 · Started: Jul 17, 2017

Contact the study team

Official record on ClinicalTrials.gov — NCT03199651

Locations in the U.S.

OhioOhio State University Comprehensive Cancer Center, Columbus

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.